PetMed Express director granted 55,555 restricted shares
Batushansky Peter reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Batushansky Peter reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express Inc. director Peter Batushansky reported a grant of 55,555 shares of common stock as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan. The award vests in full on August 11, 2027, subject to his continued service on the Board of Directors, bringing his direct holdings to 91,928 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 55,555 | $0.00 | $0.00 |
Footnotes (1)
- F1. Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on August 11, 2027, subject to continued service on the Board of Directors.
Key Figures
Key Terms
restricted stock award financial
2024 Omnibus Incentive Plan financial
continued service on the Board of Directors financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did PETS director Peter Batushansky report?
What type of equity award did PETS grant to director Peter Batushansky?
Was the PETS Form 4 transaction a market purchase or sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.